Company news
Ocumension Therapeutics news in 2021
Ocumension Therapeutics's news releases, calls and decks from 2021, newest first.
Ocumension Therapeutics Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
August 25, 2021
Ocumension Therapeutics Announces 2021 Interim Results
August 20, 2021
Notice of extraordinary general meeting
August 10, 2021
Voluntary announcement ind application received for a phase iii clinical trial of OT-101 in china
May 12, 2021
Completion of the transactions under share purchase agreement
April 23, 2021
Voluntary announcement approval for commencement of initial pediatric study plan for OT-101 in the united states
April 22, 2021
Ocumension Therapeutics: (I) discloseable transactions relating to the exclusive license agreement and the share purchase agreement and (ii) the warrant subscription agreement with alimera sciences, inc.
April 14, 2021
Voluntary announcement first patient enrolled in the phase iii clinical trial of OT-101 in the united states and the planned real world study for OT-101 in china
April 7, 2021
Voluntary announcement new drug application for OT-401 accepted by the national medical products administration
April 7, 2021
Change of non-executive director
March 19, 2021
Voluntary announcement inclusion of the shares of the company in the hong kong stock connect list under the shenzhen-hong kong stock connect
March 15, 2021
Voluntary announcement second phase iii clinical trial of OT-301 approved in china
March 3, 2021
Voluntary announcement selection of the shares of the company as a constituent of certain indexes of hang seng indexes company limited
March 1, 2021